Evidence map›Paper›PMID 28949787›Full record

ArticleHuman vaccines & immunotherapeutics2017

Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

Sarah B Lloyd, Keith P Niven, Ben R Kiefel, David C Montefiori, Arnold Reynaldi, Miles P Davenport, Stephen J Kent, Wendy R Winnall

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sarah B Lloyda Department of Microbiology and Immunology , The University of Melbourne, Peter Doherty Institute for Infection and Immunity , Victoria , Australia.
Keith P Nivenb Affinity BIO Pty Ltd. , Melbourne , VIC , Australia.
Ben R Kiefelb Affinity BIO Pty Ltd. , Melbourne , VIC , Australia.
David C Montefioric Department of Medicine , Duke University Medical Center , Durham , North Carolina , USA.
Arnold Reynaldid Infection Analytics Program, Kirby Institute for Infection and Immunity , University of New South Wales Australia , Sydney , Australia.
Miles P Davenportd Infection Analytics Program, Kirby Institute for Infection and Immunity , University of New South Wales Australia , Sydney , Australia.
Stephen J Kenta Department of Microbiology and Immunology , The University of Melbourne, Peter Doherty Institute for Infection and Immunity , Victoria , Australia.
Wendy R Winnalla Department of Microbiology and Immunology , The University of Melbourne, Peter Doherty Institute for Infection and Immunity , Victoria , Australia.
University of Melbourne · AUUNSW Sydney · AUAlfred Health · AUDuke Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While broadly neutralizing antibodies (bnAbs) are a promising preventative and therapeutic tool for HIV infection, production is difficult and expensive. Production of antibody-like fragments in bacterial cytoplasm provides a cheaper alternative. This work explored the transplantation of the complementarity determining regions of the anti-HIV bnAbs PGT121 and 10E8 onto a single-chain variable fragment (scFv) scaffold, previously discovered through a novel screening platform. The scaffolded 10E8 scFv, but not the scaffolded PGT121 scFv, was soluble in bacterial cytoplasm, enabling efficient production in bacteria. Three additional multimeric constructs employing the scaffolded 10E8 scFv were also generated and soluble versions produced in bacteria. However, the constructs were found to have substantially lost anti-HIV binding function and had completely abrogated neutralizing activity. Overall, while this study provides a proof-of-concept for anti-HIV bnAb construct production in bacterial cytoplasm, future refinement of these technologies will be required to realize the goal of producing inexpensive and effective bnAb-like tools for the control of HIV.

Indexed as

Antibodies, NeutralizingBacteriaEscherichia coliHIV-1HIV AntibodiesHIV InfectionsHumansNeutralization TestsProof of Concept StudySingle-Chain AntibodiesAntibodies, NeutralizingHIV AntibodiesSingle-Chain Antibodies10E8Broadly neutralizing antibodiesDiabodiesE. coli ExpressionHuman immunodeficiency virusPGT121Single-chain variable fragment antibodiesTandem-scFv

Identifiers

PMID28949787
PMCPMC5703365
OpenAlexW2760494611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.